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Introduction
Prostate cancer is the most commonly diagnosed cancer in men and the third leading cause of cancer-related death in men in Canada and the U.S. 1, 2 There are now several approved treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on docetaxel chemotherapy. 3, 4 Cabazitaxel is a novel tubulin-binding taxane with activity in taxane-resistant solid tumours. 5 In the phase 3 TROPIC trial, cabazitaxel plus prednisone improved overall survival (OS) compared to mitoxantrone plus prednisone and became established as a standard second-line treatment for mCRPC. 6 Treatment with abiraterone, enzalutamide, and radium-223 have also shown a survival advantage in this setting. [7] [8] [9] Without head-to-head randomized controlled trials or sequencing studies, there is little evidence to guide which agent is best for a given patient and how the different agents should be sequenced to optimize outcomes. Until such data becomes available, identifying and understanding prognostic and predictive factors for patients progressing after first-line chemotherapy for mCRPC could aid patients and physicians with treatment decisions.
Prognostic factors correlate with outcome independent of treatment effect. Predictive factors inform on the probability of response to a treatment and, therefore, are more useful in helping clinicians determine whether a patient should be treated with a specific drug. Prognostic factors for mCRPC patients receiving first-line docetaxel are well-described and include: age, performance status, presence of visceral disease, hemoglobin, alkaline phosphatase (ALP), albumin, lactate dehydrogenase (LDH), prostate-specific antigen (PSA) level, PSA doubling time, and Gleason score. [10] [11] [12] [13] [14] [15] [16] [17] For patients who receive second-line chemotherapy, an analysis of data from the TROPIC trial identified nine prognostic variables: Eastern Cooperative Oncology Group (ECOG) performance status, presence of pain, measurable disease, presence of visceral disease, time since last docetaxel use, duration of hormonal use, hemoglobin, PSA, and ALP. 18 However, this analysis was limited in that it only included patients enrolled in the TROPIC trial at a time when abiraterone and enzalutamide were not commonly used. A further subanalysis of the experimental arm of the TROPIC trial also identified severe neutropenia during treatment as a favourable prognostic factor. 19 In a separate study of 47 patients treated with cabazitaxel, a pre-treatment elevated neutrophil-to-lymphocyte ratio (NLR) greater than 3.83 was found to confer a worse prognosis, with hazard ratio (HR) of 3.0. 20 In routine clinical practice, little is known about the prognostic factors for patients receiving second-line chemotherapy, including the impact of prior treatments.
Predictive factors for patients receiving chemotherapy for mCRPC are less well-studied. A prospective study assessing the role of the androgen receptor splice variant 7 (AR-V7) as a predictive biomarker for patients with mCRPC showed that AR-V7 did not predict for response to taxanes, but AR-V7-positive patients had superior outcomes with the taxanes compared to abiraterone or enzalutamide. 21 A subanalysis of the experimental arm of the TROPIC trial identified that in addition to being a favourable prognostic factor, severe neutropenia was also a predictor of response. 19 A high Gleason score (≥8) was shown to correlate with increased progression-free survival (PFS) in a small retrospective study. 22 This would be consistent with the theory that more aggressive disease benefits from cabazitaxel. Multiple studies have also assessed the impact of prior abiraterone or enzalutamide on activity of cabazitaxel and all have shown that cabazitaxel continues to be active in this setting. [23] [24] [25] [26] [27] Ultimately, there is insufficient evidence to know which clinical factors will predict for a response to cabazitaxel.
Given the dearth of information regarding prognostic and predictive factors for patients treated with cabazitaxel in routine clinical practice, we analyzed data from patients treated with cabazitaxel as part of the Canadian Early Access Program (C-EAP) to better understand routine clinical factors that may influence prognosis and identify which factors may predict for treatment response.
Methods
Inclusion criteria for enrollment in the C-EAP (NCT01254279) were: diagnosis of mCRPC; progression on or after treatment with docetaxel; ECOG performance status <2; life expectancy >3 months; and adequate bone marrow, cardiac, kidney, and liver function. Exclusion criteria included active peripheral neuropathy or stomatitis. Patients were treated until disease progression, unacceptable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent or death. Primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) was permitted. 26 Patients from four centres in Ontario and one in Quebec were included. Data from the C-EAP was supplemented by a retrospective chart review including patient and disease factors, treatment factors, and baseline laboratory values. Box 1 describes the variables that were collected and used in the statistical models.
Frequencies and percentages were used to describe patients' baseline characteristics, treatment exposure, and grade 3-4 toxicities. Exploratory analyses were conducted to identify factors that predict for PSA response and PSA progression. PSA response was defined as reduction of baseline PSA by ≥50%. PSA primary progression was defined as an increase in PSA by ≥25% by day 84 after the first dose of cabazitaxel and does not meet the criteria for PSA response. 28 Each explanatory variable was analyzed by univariable logistic regression and Cox proportional hazard method for PSA response and survival, respectively. Variables were chosen for the multivariable models if p<0.15 on univariable analysis. Model validation was performed using Hosmer and Lemeshow method. Data analysis was completed with Statistical Analysis Software (SAS) Version 9.3.
The C-EAP and this study were sponsored by Sanofi Canada.
Results
Forty-five patients enrolled in the C-EAP were included in this study. Baseline characteristics are listed in Table 1 . 
Metastatic CRPC treated with cabazitaxel
Median age was 65 years (range 49-82), with 91.1% of patients having an ECOG performance status of zero or one. Most patients had pain at the start of treatment (68.9%). Only 22.2% of patients had visceral metastases and 58% had bone-only disease. The median time since last dose of docetaxel was 9.4 months (range 0.7-56.8). One-third of patients previously used abiraterone. Primary prophylaxis with G-CSF was given to 53.5% of patients. Dose reductions were required in 28% and dose delays in 51%. Median number of cycles was six (range . For patients in the C-EAP, the most common adverse events were neutropenia, anemia, and fatigue. Grade 3-4 diarrhea occurred in 11% of patients. Febrile neutropenia occurred in 9% of patients.
The PSA response rate was 45.2% with PSA progression as best response observed in 21.4% of patients. The followup period ranged from 3.4-38.7 months, during which time 37 deaths occurred (82.2%) and median survival was 11.2 months.
Prognostic factors
The impact of clinical factors on survival is described in Table 2 
Predictive factors

PSA response
The effect of clinical variables on PSA response is described in Table 3 . Univariable analysis for predictive factors identified three factors to be included in the multivariable model: the presence of visceral metastases (odds ratio [OR] 4.85; 95% CI 0.85-27.7; p = 0.076), primary prophylaxis with G-CSF (OR 4.06; 95% CI 1.12 14.8; p=0.034), and development of any grade 3-4 toxicity (OR 6.13; 95% CI 1.98- 34.35; p=0.039). In the multivariable analysis, none were independent predictors of PSA response.
PSA progression
Among patients enrolled in the C-EAP, only nine had primary PSA progression as defined in this study. The impact of clinical factors on primary progression is outlined in Table  4 . On univariable analysis, the factors that had the most significant impact on primary PSA progression were ECOG performance status ≥2 (OR 9.14; 95% CI 0.72-115.5; p=0.09), prior abiraterone (OR 0.10; 95% CI 0.01-0.87; p=0.04), and receipt of primary prophylaxis with G-CSF (OR 0.08; 95% CI 0.01-0.73; p=0.03). Multivariable analysis was not performed due to the occurrence of less than 15 events.
Discussion
Prognostic factors
In this study, we present the first analysis of clinical prognostic and predictive factors for real-world patients with mCRPC receiving cabazitaxel. Among patients enrolled in the C-EAP, only low hemoglobin was associated with worse OS. This finding is consistent with previously published data on prognostic factors in patients receiving second-line chemotherapy for mCRPC. 18 However, eight other factors previously identified as prognostic factors for patients receiving cabazitaxel (performance status, time interval since prior docetaxel use, presence of visceral disease, presence of pain, duration of hormonal treatments, PSA level, and ALP) were not found to be significant in the C-EAP cohort. Presence of visceral metastases has been shown to be strongly prognostic for patients receiving docetaxel, 17 however, visceral metastases did not seem to influence prognosis for patients receiving cabazitaxel. Furthermore, there has been great interest in the role of markers of systemic inflammation as a prognostic factor for patients with mCRPC. Pre-treatment NLR is a marker of systemic inflammation that has been shown to influence prognosis for patients with mCRPC receiving ketoconazole 29 and docetaxel. 30 An ad-hoc analysis of the TROPIC trial demonstrated that patients who developed grade ≥3 neutropenia while receiving cabazitaxel had an improved survival (HR 0.65; 95% CI 0.43-0.97; p=0.035) and that low NLR is also independently associated with improved survival. 19 However, in the C-EAP cohort, neither NLR, nor development of grade ≥3 neutropenia influenced prognosis. No factors analyzed from the C-EAP were independently associated with better OS. Metastatic CRPC treated with cabazitaxel 
Predictive factors
We did not identify factors independently associated with PSA response in our study. On univariable analysis the presence of visceral disease and development of grade 3-4 neutropenia were associated with PSA response. Visceral disease is a well-documented prognostic factor; 17 however, visceral disease has not previously been shown to be predictive of response to treatment. Post-hoc analysis of phase 3 trials of abiraterone and enzalutamide for post-docetaxel mCRPC patients showed that visceral metastases did not impact PSA response. 31, 32 In the C-EAP, Gleason score also did not predict response, as was shown previously. 22 The starting dose of cabazitaxel has also been of interest to researchers. The C-EAP population did not have any difference in response for patients who started cabazitaxel with a dose reduction. A recent phase 3 trial of reduced dose of cabazitaxel (20 mg/m 2 vs. 25 mg/m 2 ) showed that response and benefit were noninferior for the lower dose compared to the higher dose. 33 This study does not support the utility of visceral metastases, Gleason score, or starting dose as predictive factors for response to cabazitaxel.
Inflammatory markers have also been investigated for predicting response to treatment. An NLR of <5 has been shown to be predictive of PSA response to abiraterone. 34 In a subgroup analysis of the TROPIC trial, Lorente et al demonstrated that lower NLR (≤3.0) was associated with an improved response to cabazitaxel. 35 These results were not replicated in the C-EAP population. In this real-world population, this study did not show that lower NLR predicted for PSA response. Lorente et al also reported that a change from high to low NLR during treatment was associated with response. However, data from the C-EAP was not available to further investigate this association.
Another clinical factor of interest for predicting response is timing and sequencing of lines of therapy. It has been previously shown that prior abiraterone does not impact the response rate for patients treated with cabazitaxel. [23] [24] [25] [26] [27] The same study also found that prior abiraterone or the duration or response to abiraterone did not influence treatment response to cabazitaxel. This study was done prior to approvals of enzalutamide and radium-223, so these factors could not be addressed.
Another important sequencing issue is the time elapsed between receiving docetaxel and cabazitaxel. On univariable analysis, time since last docetaxel use did not significantly change the likelihood of PSA response. Ultimately, this study confirmed some findings about factors that do not influence PSA response or progression, but failed to identify factors that would be clinically useful for helping the clinician predict who will or will not benefit from cabazitaxel. Therefore, practitioners are left choosing patients based on clinical trial eligibility, as outlined in the TROPIC trial, and their clinical judgement.
Limitations
The results of this study should be considered within the context of several limitations. It is a retrospective study of patients enrolled in a prospective study. The small number of patients included in this study could limit its statistical power to detect smaller differences. LDH was previously identified as a prognostic factor, but could not be included in this study due to a high rate of missing values. Performance status is also a strong predictor for prognosis, but since most patients included in this study were ECOG 0-1, there was little variability to demonstrate a difference in survival. Furthermore, there have been a number of advances in the treatment of mCRPC since the C-EAP, including the introduction of enzalutamide before and after docetaxel, as well as docetaxel and abiraterone for metastatic castrate-sensitive prostate cancer. These changes may influence prognostic and predictive factors for patients receiving cabazitaxel.
Future directions
In this secondary analysis of patients enrolled in the cabazitaxel C-EAP, we did not identify any clear clinical factors that predict for survival or PSA response. Cabazitaxel is now more widely available, therefore, larger prospective data registry studies of real-world patients may be feasible for enhancing our understanding of which patients benefit the most from cabazitaxel. The landscape for treating metastatic prostate cancer is rapidly changing, therefore, such registries will be valuable sources of information for understanding issues with treatment sequencing in greater detail.
Our results confirm that cabazitaxel is an active agent in mCRPC, but choosing patients for treatment based on clinical factors alone does not appear to be a viable approach. This study, therefore, highlights the need for a deeper understanding of the disease at the molecular level, to facilitate better patient selection. The biomarkerdriven TAXYNERGY trial looked at an early switch from one taxane to another in patients that were not responding or only partially responding. 36 In this study, a reduction of androgen receptor nuclear localization (ARNL) in circulating tumour cells (CTCs) was associated with an increased PSA response. ARNL is a promising biomarker for response or progression in patients receiving taxane therapy. Further assessment of androgen receptor variants in CTCs as biomarkers for response is currently underway (NCT02269982). To complicate matters, published phase 3 trials CHAARTED, 37 STAMPEDE, 38, 39 and LATITUDE 40 have shown survival benefit for docetaxel and abiraterone in the metastatic castrate-sensitive setting.
At this time, little is known about how clinical factors and biomarkers will play a role in choosing the appropri-Metastatic CRPC treated with cabazitaxel ate timing and patient for cabazitaxel. The Prostate Cancer Clinical Trials Working Group's updated recommendations call for serial analysis of tumour and blood-based biomarkers to be incorporated into clinical trials to better understand prognostic and predictive biomarkers. 41 
Conclusion
This study failed to reproduce findings from other studies that identified clinical factors associated with survival or PSA response to treatment with cabazitaxel. As previously described, lower hemoglobin was associated with poorer prognosis and prior abiraterone did not influence prognosis or treatment response. This study highlights the difficulty of using clinical factors alone to choose patients for second-line cabazitaxel in the real-world.
